Abstract

MSK is committed to the discovery and development of new tools and therapeutic agents for cancer detection, prevention, and treatment. The mission of the Organic Synthesis Core is to provide chemical synthesis services to Center members through a state-of-the art facility staffed by expert professional personnel in chemical synthesis. The Core operates at the interface of chemistry, biology, and medicine, and has the capability of supporting medicinal chemistry efforts to produce and evolve lead candidates and tool compounds in support of Center investigators. The work of the Core has greatly facilitated preclinical studies at the Center. The Core synthesizes novel molecules that are not readily available, by either following described procedures, or by developing new and more suitable methods of synthesis.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084824
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Nashat, Melissa A; Ricart Arbona, Rodolfo J; Lepherd, Michelle L et al. (2018) Ivermectin-compounded Feed Compared with Topical Moxidectin-Imidacloprid for Eradication of Demodex musculi in Laboratory Mice. J Am Assoc Lab Anim Sci 57:483-497
Roxburgh, Campbell S; Fenig, Yaniv M; Cercek, Andrea et al. (2018) Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits. Ann Surg Oncol :
Forde, Patrick M; Chaft, Jamie E; Smith, Kellie N et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 378:1976-1986
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Buckley, Benjamin J; Aboelela, Ashraf; Minaei, Elahe et al. (2018) 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer. J Med Chem 61:8299-8320
Geller, Shamir; Canavan, Theresa N; Pulitzer, Melissa et al. (2018) ALK-positive primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature. Int J Dermatol 57:515-520
Assel, Melissa; Dahlin, Anders; Ulmert, David et al. (2018) Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 73:961-967
Pak, Linda M; Gonen, Mithat; Seier, Kenneth et al. (2018) Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Abdom Radiol (NY) 43:2113-2118
McHugh, Deaglan J; Root, James C; Nelson, Christian J et al. (2018) Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? Cancer 124:1326-1334
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386

Showing the most recent 10 out of 8799 publications